Application of targeting STAT1 inhibitor in treatment of immune thrombocytopenia and method

A technology of thrombocytopenia and application method, applied in the field of biomedicine, can solve the problem of increased risk of bacterial infection, and achieve the effect of treating immune thrombocytopenia, high bioavailability and good safety

Pending Publication Date: 2021-11-23
SUZHOU UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Splenectomy patients at increased risk of bact

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of targeting STAT1 inhibitor in treatment of immune thrombocytopenia and method
  • Application of targeting STAT1 inhibitor in treatment of immune thrombocytopenia and method
  • Application of targeting STAT1 inhibitor in treatment of immune thrombocytopenia and method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] An application of a STAT1 nuclear import / activation inhibitor in the treatment of immune thrombocytopenia, the application is that the STAT1 activation inhibitor increases the number of platelets, and the inhibitor is fludarabine.

Embodiment 2

[0042] An application of a STAT1 nuclear import / activation inhibitor in the treatment of immune thrombocytopenia, the application is that the STAT1 nuclear import inhibitor increases the number of platelets, and the inhibitor is ivermectin.

Embodiment 3

[0044] A method for preparing a fludarabine solution for treating immune thrombocytopenia by using a STAT1 activation inhibitor, comprising the steps of:

[0045] S1: Weigh the STAT1 activation inhibitor fludarabine;

[0046] S2: dissolving the STAT1 activation inhibitor fludarabine weighed in step S1 in DMSO;

[0047] S3: use physiological saline to dilute the DMSO in step S2,

[0048] Wherein, the final volume content of DMSO in the diluted solution is 0-5%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a targeting STAT1 inhibitor in treatment of immune thrombocytopenia and a method. An STAT1 nuclear inhibitor ivermectin and an STAT1 activation inhibitor fludarabine are adopted, and the number of platelets of an immune thrombocytopenia mouse model is increased by injecting the activation inhibitor or the nuclear inhibitor. In the abovementioned way, the fludarabine is a fluorinated nucleotide analogue of arabinoside, is free of radioactivity and is a small-molecule phosphorylation inhibitor; meanwhile, the ivermectin is a small-molecule inhibitor introduced by an input protein alpha/beta 1 mediated cell nucleus, the ivermectin and the small-molecule inhibitor are high in bioavailability, are widely applied to treatment of various blood system diseases, are good in safety, are applied to treatment of the immune thrombocytopenia and are safe, effective and high in compliance.

Description

technical field [0001] The invention relates to the application of a drug for treating immune thrombocytopenia, which belongs to the field of biomedicine, and in particular relates to an application method of a targeted STAT1 inhibitor in the treatment of immune thrombocytopenia. Background technique [0002] Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelet counts and associated increased risk of bleeding complications. The annual incidence of ITP is approximately 2 to 6 cases per 100,000 children and 3 cases per 100,000 adults. Importantly, ITP is also secondary to many other diseases, including autoimmune diseases such as systemic lupus erythematosus, cancer, and viral diseases such as hepatitis C (HCV), AIDS, and novel coronavirus pneumonia (COVID-19), among others. In addition, it has been recently reported that some new crown vaccines can also cause ITP risk. ITP is the result of a cumulative multicellular mechanism, inclu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/52A61K31/7048A61P7/04A61P37/02
CPCA61K45/00A61K31/52A61K31/7048A61P7/04A61P37/02
Inventor 刘合宾熊伊韦
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap